Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Psilocybin - COMPASS Pathways

Drug Profile

Psilocybin - COMPASS Pathways

Alternative Names: COMP-360; Psilocybine

Latest Information Update: 09 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator COMPASS Pathways
  • Developer COMPASS Pathways; Imperial College of Science, Technology and Medicine; Johns Hopkins University
  • Class Analgesics; Anti-infectives; Anti-inflammatories; Antidepressants; Antineoplastics; Antipsychotics; Anxiolytics; Behavioural disorder therapies; Dimethylamines; Drug withdrawal therapies; Indoles; Mood stabilisers; Neuropsychotherapeutics; Organophosphorus compounds; Phytotherapies; Small molecules
  • Mechanism of Action ATP-binding cassette transporter modulators; Serotonin 2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Anorexia nervosa; Bipolar depression; Depressive disorders; Major depressive disorder; Pervasive child development disorders; Post-traumatic stress disorders; Somatoform disorders

Most Recent Events

  • 07 Sep 2022 Phase-II clinical trials in Pervasive child development disorders (In adults) in United Kingdom (PO) before September 2022
  • 07 Sep 2022 Compass Pathways submits phase II protocol to the US FDA in Depressive disorders (Treatment-resistant) before September 2022
  • 07 Sep 2022 Compass Pathways plans a phase II trial in Depression (Treatment-resistant) in USA in Q2 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top